External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study

Daniel Y.C. Heng; Wanling Xie; Meredith M. Regan; Lauren C. Harshman; Georg A. Bjarnason; Ulka N. Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min Han Tan; Sun Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I. Rini; Toni K. Choueiri

doi:10.1016/S1470-2045(12)70559-4

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Lauren C. Harshman, Georg A. Bjarnason, Ulka N. Vaishampayan, Mary Mackenzie, Lori Wood, Frede Donskov, Min Han Tan, Sun Young Rha, Neeraj Agarwal, Christian Kollmannsberger, Brian I. Rini, Toni K. Choueiri

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

664 Citations (Scopus)

Abstract

Background: The International Metastatic Renal-Cell Carcinoma Database Consortium model offers prognostic information for patients with metastatic renal-cell carcinoma. We tested the accuracy of the model in an external population and compared it with other prognostic models. Methods: We included patients with metastatic renal-cell carcinoma who were treated with first-line VEGF-targeted treatment at 13 international cancer centres and who were registered in the Consortium's database but had not contributed to the initial development of the Consortium Database model. The primary endpoint was overall survival. We compared the Database Consortium model with the Cleveland Clinic Foundation (CCF) model, the International Kidney Cancer Working Group (IKCWG) model, the French model, and the Memorial Sloan-Kettering Cancer Center (MSKCC) model by concordance indices and other measures of model fit. Findings: Overall, 1028 patients were included in this study, of whom 849 had complete data to assess the Database Consortium model. Median overall survival was 18·8 months (95% 17·6-21·4). The predefined Database Consortium risk factors (anaemia, thrombocytosis, neutrophilia, hypercalcaemia, Karnofsky performance status <80%, and <1 year from diagnosis to treatment) were independent predictors of poor overall survival in the external validation set (hazard ratios ranged between 1·27 and 2·08, concordance index 0·71, 95% CI 0·68-0·73). When patients were segregated into three risk categories, median overall survival was 43·2 months (95% CI 31·4-50·1) in the favourable risk group (no risk factors; 157 patients), 22·5 months (18·7-25·1) in the intermediate risk group (one to two risk factors; 440 patients), and 7·8 months (6·5-9·7) in the poor risk group (three or more risk factors; 252 patients; p<0·0001; concordance index 0·664, 95% CI 0·639-0·689). 672 patients had complete data to test all five models. The concordance index of the CCF model was 0·662 (95% CI 0·636-0·687), of the French model 0·640 (0·614-0·665), of the IKCWG model 0·668 (0·645-0·692), and of the MSKCC model 0·657 (0·632-0·682). The reported versus predicted number of deaths at 2 years was most similar in the Database Consortium model compared with the other models. Interpretation: The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis. Funding: None.

Original language	English
Pages (from-to)	141-148
Number of pages	8
Journal	The Lancet Oncology
Volume	14
Issue number	2
DOIs	https://doi.org/10.1016/S1470-2045(12)70559-4
Publication status	Published - 2013 Feb

Bibliographical note

Funding Information:
DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. LCH has an advisory role at Novartis and Pfizer and has received research funding from Bristol-Myers Squibb, Novartis, and Genentech. GAB has a consultant and advisory role at Pfizer and has received honoraria and research funding from Pfizer. MM has an advisory role at Novartis and Pfizer and has received research funding from both. LW has an advisory role at Pfizer and Novartis and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. UNV has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. S-YR has an advisory role at Novartis, Pfizer, and GlaxoSmithKline, and has received research funding from Novartis and Bayer Korea. FD has received research funding from Novartis. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. BIR has an advisory role at Pfizer, GlaxoSmithKline, Aveo, Bayer, Onyx, and has received research funding from GlaxoSmithKline and Pfizer. TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. WX, MMR, M-HT, and NA declare that they have no conflicts of interest.

All Science Journal Classification (ASJC) codes

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(12)70559-4

Cite this

Heng, D. Y. C., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M. H., Rha, S. Y., Agarwal, N., Kollmannsberger, C., Rini, B. I., & Choueiri, T. K. (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. The Lancet Oncology, 14(2), 141-148. https://doi.org/10.1016/S1470-2045(12)70559-4

@article{5b89657d915944439c7292d1ff02806c,

title = "External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study",

abstract = "Background: The International Metastatic Renal-Cell Carcinoma Database Consortium model offers prognostic information for patients with metastatic renal-cell carcinoma. We tested the accuracy of the model in an external population and compared it with other prognostic models. Methods: We included patients with metastatic renal-cell carcinoma who were treated with first-line VEGF-targeted treatment at 13 international cancer centres and who were registered in the Consortium's database but had not contributed to the initial development of the Consortium Database model. The primary endpoint was overall survival. We compared the Database Consortium model with the Cleveland Clinic Foundation (CCF) model, the International Kidney Cancer Working Group (IKCWG) model, the French model, and the Memorial Sloan-Kettering Cancer Center (MSKCC) model by concordance indices and other measures of model fit. Findings: Overall, 1028 patients were included in this study, of whom 849 had complete data to assess the Database Consortium model. Median overall survival was 18·8 months (95% 17·6-21·4). The predefined Database Consortium risk factors (anaemia, thrombocytosis, neutrophilia, hypercalcaemia, Karnofsky performance status <80%, and <1 year from diagnosis to treatment) were independent predictors of poor overall survival in the external validation set (hazard ratios ranged between 1·27 and 2·08, concordance index 0·71, 95% CI 0·68-0·73). When patients were segregated into three risk categories, median overall survival was 43·2 months (95% CI 31·4-50·1) in the favourable risk group (no risk factors; 157 patients), 22·5 months (18·7-25·1) in the intermediate risk group (one to two risk factors; 440 patients), and 7·8 months (6·5-9·7) in the poor risk group (three or more risk factors; 252 patients; p<0·0001; concordance index 0·664, 95% CI 0·639-0·689). 672 patients had complete data to test all five models. The concordance index of the CCF model was 0·662 (95% CI 0·636-0·687), of the French model 0·640 (0·614-0·665), of the IKCWG model 0·668 (0·645-0·692), and of the MSKCC model 0·657 (0·632-0·682). The reported versus predicted number of deaths at 2 years was most similar in the Database Consortium model compared with the other models. Interpretation: The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis. Funding: None.",

author = "Heng, {Daniel Y.C.} and Wanling Xie and Regan, {Meredith M.} and Harshman, {Lauren C.} and Bjarnason, {Georg A.} and Vaishampayan, {Ulka N.} and Mary Mackenzie and Lori Wood and Frede Donskov and Tan, {Min Han} and Rha, {Sun Young} and Neeraj Agarwal and Christian Kollmannsberger and Rini, {Brian I.} and Choueiri, {Toni K.}",

note = "Funding Information: DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. LCH has an advisory role at Novartis and Pfizer and has received research funding from Bristol-Myers Squibb, Novartis, and Genentech. GAB has a consultant and advisory role at Pfizer and has received honoraria and research funding from Pfizer. MM has an advisory role at Novartis and Pfizer and has received research funding from both. LW has an advisory role at Pfizer and Novartis and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. UNV has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. S-YR has an advisory role at Novartis, Pfizer, and GlaxoSmithKline, and has received research funding from Novartis and Bayer Korea. FD has received research funding from Novartis. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. BIR has an advisory role at Pfizer, GlaxoSmithKline, Aveo, Bayer, Onyx, and has received research funding from GlaxoSmithKline and Pfizer. TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. WX, MMR, M-HT, and NA declare that they have no conflicts of interest. ",

year = "2013",

month = feb,

doi = "10.1016/S1470-2045(12)70559-4",

language = "English",

volume = "14",

pages = "141--148",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "2",

}

Heng, DYC, Xie, W, Regan, MM, Harshman, LC, Bjarnason, GA, Vaishampayan, UN, Mackenzie, M, Wood, L, Donskov, F, Tan, MH, Rha, SY, Agarwal, N, Kollmannsberger, C, Rini, BI & Choueiri, TK 2013, 'External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study', The Lancet Oncology, vol. 14, no. 2, pp. 141-148. https://doi.org/10.1016/S1470-2045(12)70559-4

TY - JOUR

T1 - External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model

T2 - A population-based study

AU - Heng, Daniel Y.C.

AU - Xie, Wanling

AU - Regan, Meredith M.

AU - Harshman, Lauren C.

AU - Bjarnason, Georg A.

AU - Vaishampayan, Ulka N.

AU - Mackenzie, Mary

AU - Wood, Lori

AU - Donskov, Frede

AU - Tan, Min Han

AU - Rha, Sun Young

AU - Agarwal, Neeraj

AU - Kollmannsberger, Christian

AU - Rini, Brian I.

AU - Choueiri, Toni K.

N1 - Funding Information: DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. LCH has an advisory role at Novartis and Pfizer and has received research funding from Bristol-Myers Squibb, Novartis, and Genentech. GAB has a consultant and advisory role at Pfizer and has received honoraria and research funding from Pfizer. MM has an advisory role at Novartis and Pfizer and has received research funding from both. LW has an advisory role at Pfizer and Novartis and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. UNV has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. S-YR has an advisory role at Novartis, Pfizer, and GlaxoSmithKline, and has received research funding from Novartis and Bayer Korea. FD has received research funding from Novartis. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. BIR has an advisory role at Pfizer, GlaxoSmithKline, Aveo, Bayer, Onyx, and has received research funding from GlaxoSmithKline and Pfizer. TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. WX, MMR, M-HT, and NA declare that they have no conflicts of interest.

PY - 2013/2

Y1 - 2013/2

N2 - Background: The International Metastatic Renal-Cell Carcinoma Database Consortium model offers prognostic information for patients with metastatic renal-cell carcinoma. We tested the accuracy of the model in an external population and compared it with other prognostic models. Methods: We included patients with metastatic renal-cell carcinoma who were treated with first-line VEGF-targeted treatment at 13 international cancer centres and who were registered in the Consortium's database but had not contributed to the initial development of the Consortium Database model. The primary endpoint was overall survival. We compared the Database Consortium model with the Cleveland Clinic Foundation (CCF) model, the International Kidney Cancer Working Group (IKCWG) model, the French model, and the Memorial Sloan-Kettering Cancer Center (MSKCC) model by concordance indices and other measures of model fit. Findings: Overall, 1028 patients were included in this study, of whom 849 had complete data to assess the Database Consortium model. Median overall survival was 18·8 months (95% 17·6-21·4). The predefined Database Consortium risk factors (anaemia, thrombocytosis, neutrophilia, hypercalcaemia, Karnofsky performance status <80%, and <1 year from diagnosis to treatment) were independent predictors of poor overall survival in the external validation set (hazard ratios ranged between 1·27 and 2·08, concordance index 0·71, 95% CI 0·68-0·73). When patients were segregated into three risk categories, median overall survival was 43·2 months (95% CI 31·4-50·1) in the favourable risk group (no risk factors; 157 patients), 22·5 months (18·7-25·1) in the intermediate risk group (one to two risk factors; 440 patients), and 7·8 months (6·5-9·7) in the poor risk group (three or more risk factors; 252 patients; p<0·0001; concordance index 0·664, 95% CI 0·639-0·689). 672 patients had complete data to test all five models. The concordance index of the CCF model was 0·662 (95% CI 0·636-0·687), of the French model 0·640 (0·614-0·665), of the IKCWG model 0·668 (0·645-0·692), and of the MSKCC model 0·657 (0·632-0·682). The reported versus predicted number of deaths at 2 years was most similar in the Database Consortium model compared with the other models. Interpretation: The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis. Funding: None.

AB - Background: The International Metastatic Renal-Cell Carcinoma Database Consortium model offers prognostic information for patients with metastatic renal-cell carcinoma. We tested the accuracy of the model in an external population and compared it with other prognostic models. Methods: We included patients with metastatic renal-cell carcinoma who were treated with first-line VEGF-targeted treatment at 13 international cancer centres and who were registered in the Consortium's database but had not contributed to the initial development of the Consortium Database model. The primary endpoint was overall survival. We compared the Database Consortium model with the Cleveland Clinic Foundation (CCF) model, the International Kidney Cancer Working Group (IKCWG) model, the French model, and the Memorial Sloan-Kettering Cancer Center (MSKCC) model by concordance indices and other measures of model fit. Findings: Overall, 1028 patients were included in this study, of whom 849 had complete data to assess the Database Consortium model. Median overall survival was 18·8 months (95% 17·6-21·4). The predefined Database Consortium risk factors (anaemia, thrombocytosis, neutrophilia, hypercalcaemia, Karnofsky performance status <80%, and <1 year from diagnosis to treatment) were independent predictors of poor overall survival in the external validation set (hazard ratios ranged between 1·27 and 2·08, concordance index 0·71, 95% CI 0·68-0·73). When patients were segregated into three risk categories, median overall survival was 43·2 months (95% CI 31·4-50·1) in the favourable risk group (no risk factors; 157 patients), 22·5 months (18·7-25·1) in the intermediate risk group (one to two risk factors; 440 patients), and 7·8 months (6·5-9·7) in the poor risk group (three or more risk factors; 252 patients; p<0·0001; concordance index 0·664, 95% CI 0·639-0·689). 672 patients had complete data to test all five models. The concordance index of the CCF model was 0·662 (95% CI 0·636-0·687), of the French model 0·640 (0·614-0·665), of the IKCWG model 0·668 (0·645-0·692), and of the MSKCC model 0·657 (0·632-0·682). The reported versus predicted number of deaths at 2 years was most similar in the Database Consortium model compared with the other models. Interpretation: The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis. Funding: None.

UR - http://www.scopus.com/inward/record.url?scp=84873080330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873080330&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(12)70559-4

DO - 10.1016/S1470-2045(12)70559-4

M3 - Article

C2 - 23312463

AN - SCOPUS:84873080330

SN - 1470-2045

VL - 14

SP - 141

EP - 148

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this